{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    43,
    85,
    86,
    89,
    92,
    105,
    106,
    109
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study drug"
      },
      {
        "id": "anchor_2",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "randomization visit"
      },
      {
        "id": "anchor_3",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline assessment"
      },
      {
        "id": "anchor_4",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening visit"
      },
      {
        "id": "anchor_5",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "informed consent"
      },
      {
        "id": "anchor_6",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "startOffset": "P3D",
        "endOffset": "P7D",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_31",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_6",
        "type": "Interval",
        "sourceText": "Continuous Glucose"
      },
      {
        "id": "rep_interval_7",
        "type": "Interval",
        "sourceText": "CGM"
      },
      {
        "id": "rep_interval_8",
        "type": "Interval",
        "sourceText": "continuous \nglucose"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P3D",
        "endOffset": "P7D",
        "sourceText": "Day -3 to Day 7"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P3D",
        "endOffset": "P7D",
        "sourceText": "from Day -3 to Day 7"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "sourceText": "2 hours after"
      },
      {
        "id": "rep_window_25",
        "type": "Continuous",
        "sourceText": "34 days post"
      },
      {
        "id": "rep_window_26",
        "type": "Continuous",
        "sourceText": "94 days post"
      },
      {
        "id": "rep_llm_1",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P24W",
        "interval": "P24W",
        "minObservations": 1,
        "exitCondition": "Completion of 24 week double blinded short term treatment period",
        "sourceText": "during the 24 week double blinded short term treatment period"
      },
      {
        "id": "rep_llm_2",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "P24W",
        "interval": "P1D",
        "minObservations": 168,
        "exitCondition": "End of treatment period",
        "sourceText": "If blood glucose is repeatedly low and a 20% reduction in total daily insulin dose cannot be avoided the daily dietary carbohydrate intake should be increased"
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "P10W",
        "endOffset": "P11W",
        "interval": "P1W",
        "minObservations": 2,
        "exitCondition": "Completion of week 11 assessment",
        "sourceText": "Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23)"
      },
      {
        "id": "rep_llm_5",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P24W",
        "interval": "PT4H",
        "minObservations": 6,
        "exitCondition": "End of lead-in or treatment phase",
        "sourceText": "performing the 6-point self monitoring blood glucose (SMBG)"
      },
      {
        "id": "rep_llm_6",
        "type": "Cycle",
        "startOffset": "-P56D",
        "endOffset": "P0D",
        "interval": "P56D",
        "minObservations": 1,
        "exitCondition": "Randomization at Day 1",
        "sourceText": "Lead-in Period window of 56 + 5 days"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "washout period"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "LEAD_IN",
          "SHORT_TERM_TREATMENT",
          "LONG_TERM_TREATMENT",
          "FOLLOW_UP"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Week 24",
          "Week 52",
          "End of Study",
          "Day 1",
          "Randomization"
        ],
        "sourceText": "[{'condition': 'Lead-in failure', 'path': ['SCREENING', 'LEAD_IN', 'EARLY_TERMINATION']}, {'condition': 'Elevated liver function tests', 'path': ['HEPATIC_ADJUDICATION', 'DISCONTINUATION']}, {'condition': 'Rescreening allowed if no criteria failed but randomization window missed', 'path': ['RESCREENING', 'LEAD_IN', 'RANDOMIZATION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Vital Signs",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 6; SINGLE signals: 2"
      },
      {
        "activityId": "Ecg",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3; SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
      },
      {
        "activityId": "Pk Sampling",
        "executionType": "Window",
        "rationale": "WINDOW signals: 3; EPISODE signals: 2; SINGLE signals: 2; RECURRING signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Glucose Monitoring",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Insulin Administration",
        "executionType": "Single",
        "rationale": "EPISODE signals: 2; SINGLE signals: 3"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 3; SINGLE signals: 1"
      },
      {
        "activityId": "Imaging",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Diary",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; RECURRING signals: 1"
      },
      {
        "activityId": "Continuous Glucose Monitoring (CGM)",
        "executionType": "Single",
        "rationale": "The protocol specifies CGM visits spanning weeks 10/11 and 22/23, requiring subjects to record sensor insertion times and collect data over these multi-day periods."
      },
      {
        "activityId": "Insulin Dose Titration",
        "executionType": "Single",
        "rationale": "The protocol describes a conditional workflow where if insulin is reduced, attempts must be made to titrate back to baseline, with specific decision points regarding reductions >20%."
      },
      {
        "activityId": "Ketone Monitoring and DKA Assessment",
        "executionType": "Single",
        "rationale": "This is a conditional workflow triggered by elevated ketones; investigators must advise extra insulin/carbohydrates and consider reeducation based on the subject's status."
      },
      {
        "activityId": "Subject Diary Review",
        "executionType": "Single",
        "rationale": "Site staff are required to review results recorded in the subject diary at each scheduled study visit."
      },
      {
        "activityId": "HbA1c Assessment",
        "executionType": "Single",
        "rationale": "The protocol specifies a specific screening assessment for HbA1c at the Week -1 Visit to determine eligibility (<=10.5%)."
      },
      {
        "activityId": "Phone Visits",
        "executionType": "Single",
        "rationale": "The amendment allows for optional phone visits to be conducted at specific scheduled intervals (Week -4, Week 2, and CGM weeks)."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "washout period"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Screening visit may consist of 2 days. Second day is to collect lab work. The length of the Qualification period is ≤ 28 days.",
        "footnoteId": "fn_1",
        "structuredCondition": "visit.duration.max(P2D) && qualification_period.duration.max(P28D)",
        "appliesToActivityIds": [
          "Screening Visit",
          "Qualification Period"
        ],
        "sourceText": "a. Screening visit may consist of 2 days. Second day is to collect lab work. The length of the Quali"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Week -8 visit needs to be within 28 days of screening visit. Week -4 visit and Week -2 visit may be scheduled ± 3 days to allow flexibility of scheduling.",
        "footnoteId": "fn_2",
        "structuredCondition": "visit(W-8).offset(Screening, P28D) && visit(W-4, W-2).window(P3D)",
        "appliesToActivityIds": [
          "Week -8 Visit",
          "Week -4 Visit",
          "Week -2 Visit"
        ],
        "sourceText": "b. Week -8 visit needs to be within 28 days of screening visit. Week -4 visit and Week -2 visit may "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "c. Optional Phone Visit - Week -4 visit can be done as a phone visit to allow flexibility for the subject in visit scheduling. If a phone visit is done, the home pregnancy kit and new week -4 visit diary should be given to the subject at the week -8 visit as well as additional glucose and ketone strips, if needed. Copies of completed diaries must be sent (scan, photo, fax) into the site prior to the phone visit so discussions can occur between the subject and site personnel about the data captured in the diaries.",
        "footnoteId": "fn_3",
        "structuredCondition": "if(visit.type == 'phone') { dispense(pregnancy_kit, diary, strips).at(W-8) && submit(diary).before(visit) }",
        "appliesToActivityIds": [
          "Week -4 Visit",
          "Home Pregnancy Kit",
          "Diary",
          "Glucose and Ketone Strips"
        ],
        "sourceText": "c. Optional Phone Visit - Week -4 visit can be done as a phone visit to allow flexibility for the su"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_after",
        "text": "d. Week -1 visit should be scheduled at least 7 days but not longer than 10 days after Week -2 visit to accommodate for CGM data collection.",
        "footnoteId": "fn_4",
        "structuredCondition": "visit(W-1).after(W-2, P7D) && visit(W-1).before(W-2, P10D)",
        "appliesToActivityIds": [
          "Week -1 Visit",
          "CGM Data Collection"
        ],
        "sourceText": "d. Week -1 visit should be scheduled at least 7 days but not longer than 10 days after Week -2 visit"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_before",
        "text": "e. If a lead-in subject fails lead-in prior to the Day 1 visit, the CGM and Meal Recording will not be required to be completed",
        "footnoteId": "fn_5",
        "structuredCondition": "if(subject.status == 'failed_lead_in') { skip(CGM, Meal Recording) }",
        "appliesToActivityIds": [
          "CGM",
          "Meal Recording"
        ],
        "sourceText": "e. If a lead-in subject fails lead-in prior to the Day 1 visit, the CGM and Meal Recording will not "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. These safety assessments; review of AEs, hypoglycemia events, and DKA episodes to be performed throughout the study according to the visit schedule as noted via “X”",
        "footnoteId": "fn_6",
        "structuredCondition": "perform(AE_Review, Hypoglycemia_Review, DKA_Review).at(all_marked_visits)",
        "appliesToActivityIds": [
          "Review of AEs",
          "Hypoglycemia events",
          "DKA episodes"
        ],
        "sourceText": "f. These safety assessments; review of AEs, hypoglycemia events, and DKA episodes to be performed th"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. If an optional phone visit is planned for week -4, the home pregnancy kit should be given to the subject at the week -8 visit.",
        "footnoteId": "fn_7",
        "structuredCondition": "if(visit(W-4).type == 'phone') { dispense(pregnancy_kit).at(W-8) }",
        "appliesToActivityIds": [
          "Home Pregnancy Kit"
        ],
        "sourceText": "g. If an optional phone visit is planned for week -4, the home pregnancy kit should be given to the "
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_at",
        "text": "h. At Week 10 & 22. If subject is an early termination, then CGM is not required. If week 10 and week 22 are optional phone visits, please refer to footnote e below and Section 5.9.4.3 CGM.",
        "footnoteId": "fn_8",
        "structuredCondition": "if(subject.status == 'early_termination') { skip(CGM) }",
        "appliesToActivityIds": [
          "CGM"
        ],
        "sourceText": "h. At Week 10 & 22. If subject is an early termination, then CGM is not required. If week 10 and wee"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_at",
        "text": "i. At Week 12 & 24. CGM Data Collection not needed if at Week 10/22 visit CGM insertion was not completed. Please refer to Section 5.9.4.3",
        "footnoteId": "fn_9",
        "structuredCondition": "if(CGM_insertion.status == 'not_completed') { skip(CGM_Data_Collection) }",
        "appliesToActivityIds": [
          "CGM Data Collection"
        ],
        "sourceText": "i. At Week 12 & 24. CGM Data Collection not needed if at Week 10/22 visit CGM insertion was not comp"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. Day 1 visit should be within 56 days +/- 5 days of the Week -8 visit. If a retest of A1C is done at Week -1, a 7 day window (added to the current lead-in period window of 56+5 days) will be allowed",
        "footnoteId": "fn_10",
        "structuredCondition": "visit(Day1).offset(W-8, P56D).window(P5D) && if(A1C_retest == true) { window.extend(P7D) }",
        "appliesToActivityIds": [
          "Day 1 Visit",
          "A1C Retest"
        ],
        "sourceText": "j. Day 1 visit should be within 56 days +/- 5 days of the Week -8 visit. If a retest of A1C is done "
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "k. Visits may be scheduled ± 1 days to allow flexibility of scheduling.",
        "footnoteId": "fn_11",
        "sourceText": "k. Visits may be scheduled ± 1 days to allow flexibility of scheduling."
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. Visits may be scheduled ± 3 days to allow flexibility of scheduling.",
        "footnoteId": "fn_12",
        "sourceText": "l. Visits may be scheduled ± 3 days to allow flexibility of scheduling."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "m. PK samples should be collected if the visit is being used as an early termination visit or if it is the subject’s regularly scheduled week 24 visit and the subject is currently taking study medication. In the event that the subject discontinues study medication but continues in the study, any PK samples required at visits should not be done",
        "footnoteId": "fn_13",
        "sourceText": "m. PK samples should be collected if the visit is being used as an early termination visit or if it "
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Change from baseline in HbA1c",
        "endpointType": "Primary",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week24"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "24 weeks"
        },
        "algorithm": "HbA1c_week24 - HbA1c_baseline",
        "successCriteria": "Statistically significant reduction compared to placebo plus adjustable insulin",
        "sourceText": "The primary objective of this study is to compare the change from baseline in HbA1c after 24 weeks of double-blinded treatment with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo p"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Percent change from baseline in total daily insulin dose",
        "endpointType": "Secondary",
        "inputs": [
          "TDI_baseline",
          "TDI_week24"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "24 weeks"
        },
        "algorithm": "((TDI_week24 - TDI_baseline) / TDI_baseline) * 100",
        "successCriteria": "Comparison of percent change between treatment groups",
        "sourceText": "Compare the percent change from baseline in total daily insulin dose with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded tr"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Percent change from baseline in body weight",
        "endpointType": "Secondary",
        "inputs": [
          "weight_baseline",
          "weight_week24"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "24 weeks"
        },
        "algorithm": "((weight_week24 - weight_baseline) / weight_baseline) * 100",
        "successCriteria": "Comparison of percent change between treatment groups",
        "sourceText": "Compare the percent change from baseline in body weight with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment"
      },
      {
        "id": "ep_4",
        "name": "Secondary: Percent of CGM readings in target range",
        "endpointType": "Secondary",
        "inputs": [
          "CGM_glucose_readings"
        ],
        "timeWindow": {
          "reference": "baseline and week 24",
          "duration": "24 hours"
        },
        "algorithm": "(count(readings > 70 AND readings <= 180) / total_readings) * 100",
        "successCriteria": "Comparison of change from baseline in percentage between groups",
        "sourceText": "Compare the change from baseline in the percent of 24-hour glucose readings obtained from CGM that falls within the target range of >70 mg/dL and <=180 mg/dL"
      },
      {
        "id": "ep_5",
        "name": "Secondary: Proportion of subjects achieving HbA1c reduction without severe hypoglycemia",
        "endpointType": "Secondary",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week24",
          "severe_hypoglycemia_events"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "24 weeks"
        },
        "algorithm": "(HbA1c_baseline - HbA1c_week24 >= 0.5) AND (severe_hypoglycemia_events == 0)",
        "successCriteria": "Higher proportion of subjects meeting criteria in treatment vs placebo",
        "sourceText": "proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit >=0.5% without severe hypoglycemia events"
      },
      {
        "id": "ep_6",
        "name": "Exploratory: Non-severe hypoglycemia events in HbA1c responders",
        "endpointType": "Exploratory",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week24",
          "non_severe_hypoglycemia_count"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "24 weeks"
        },
        "algorithm": "IF (HbA1c_baseline - HbA1c_week24 > 0.5) THEN count(non_severe_hypoglycemia_events)",
        "successCriteria": "Comparison of event frequency per subject between groups in the responder subset",
        "sourceText": "compare the number of non-severe hypoglycemic events per subject in those achieving a HbA1c reduction of >0.5% on dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable ins"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from baseline in HbA1c",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "Week 24 value - Baseline value",
        "baselineDefinition": "Value prior to the start of double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "%"
      },
      {
        "id": "dv_2",
        "name": "Percent change from baseline in total daily insulin dose",
        "variableType": "PercentChange",
        "sourceVariables": [
          "Total daily insulin dose"
        ],
        "derivationRule": "((Week 24 value - Baseline value) / Baseline value) * 100",
        "baselineDefinition": "Value prior to the start of double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "%"
      },
      {
        "id": "dv_3",
        "name": "Percent change from baseline in body weight",
        "variableType": "PercentChange",
        "sourceVariables": [
          "Body weight"
        ],
        "derivationRule": "((Week 24 value - Baseline value) / Baseline value) * 100",
        "baselineDefinition": "Value prior to the start of double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "%"
      },
      {
        "id": "dv_4",
        "name": "Change from baseline in mean value of 24-hour CGM glucose readings",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "CGM glucose readings"
        ],
        "derivationRule": "Week 24 mean - Baseline mean",
        "baselineDefinition": "Mean value obtained from CGM prior to double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "mg/dL"
      },
      {
        "id": "dv_5",
        "name": "Change from baseline in mean amplitude of glucose excursion (MAGE)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "CGM glucose readings"
        ],
        "derivationRule": "Week 24 MAGE - Baseline MAGE",
        "baselineDefinition": "MAGE calculated from CGM readings prior to double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "mg/dL"
      },
      {
        "id": "dv_6",
        "name": "Change from baseline in percent of 24-hour CGM readings within target range",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "CGM glucose readings"
        ],
        "derivationRule": "Week 24 percent in range - Baseline percent in range (Target: >70 and <=180 mg/dL)",
        "baselineDefinition": "Percent of readings in target range prior to double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "%"
      },
      {
        "id": "dv_7",
        "name": "Proportion of subjects achieving HbA1c reduction >=0.5% without severe hypoglycemia",
        "variableType": "Composite",
        "sourceVariables": [
          "HbA1c",
          "Severe hypoglycemia events"
        ],
        "derivationRule": "Count of subjects with (HbA1c change <= -0.5% AND zero severe hypoglycemia events) / Total subjects",
        "baselineDefinition": "HbA1c value prior to double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "Proportion"
      },
      {
        "id": "dv_8",
        "name": "Proportion of subjects with HbA1c < 7.0%",
        "variableType": "Categorical",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "Count of subjects with HbA1c < 7.0% at Week 24 / Total subjects",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "Proportion"
      },
      {
        "id": "dv_9",
        "name": "Change from baseline in fasting plasma glucose (FPG)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "FPG"
        ],
        "derivationRule": "Week 24 value - Baseline value",
        "baselineDefinition": "Value prior to the start of double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "mg/dL"
      },
      {
        "id": "dv_10",
        "name": "Change from baseline in seated systolic blood pressure (hypertensive subgroup)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Seated SBP",
          "Seated DBP"
        ],
        "derivationRule": "Week 24 SBP - Baseline SBP for subjects with Baseline SBP >=140 or DBP >=90",
        "baselineDefinition": "Value prior to the start of double-blind treatment",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in provided text",
        "unit": "mmHg"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Lead In",
        "Short Term Treatment",
        "Long Term Treatment",
        "Follow Up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Lead In",
          "trigger": "Progress to Lead In"
        },
        {
          "fromState": "Lead In",
          "toState": "Short Term Treatment",
          "trigger": "Progress to Short Term Treatment"
        },
        {
          "fromState": "Short Term Treatment",
          "toState": "Long Term Treatment",
          "trigger": "Progress to Long Term Treatment"
        },
        {
          "fromState": "Long Term Treatment",
          "toState": "Follow Up",
          "trigger": "Progress to Follow Up"
        },
        {
          "fromState": "Short Term Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Long Term Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Lead In": "LEAD_IN",
        "Short Term Treatment": "SHORT_TERM_TREATMENT",
        "Long Term Treatment": "LONG_TERM_TREATMENT",
        "Follow Up": "FOLLOW_UP",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Compare dapagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 180.0,
            "unit": "mg"
          },
          {
            "amount": 70.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "24 weeks",
        "sourceText": "alls within the target range of 70 mg/dL and 180 mg/dL with dapagliflozin 5 mg or 10 mg plus adjustable insulin versus placebo plus adjustable insulin after 24 weeks of double-blinded treatment  Co"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Coated Tablets",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          }
        ],
        "sourceText": "es both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed: Study Drug for MB102230 Medication Potency IP/Non-IP Dapagliflozin Film C"
      },
      {
        "id": "dosing_3",
        "treatmentName": "Because dapagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          }
        ],
        "sourceText": "etion appeared to be virtually identical in this T1DM population to that previously described in T2DM subjects, correcting for baseline differences in glycemic control and eGFR between the studies. Be"
      },
      {
        "id": "dosing_4",
        "treatmentName": "ETHICAL CONSIDERATIONS",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 2.1,
            "unit": "g"
          }
        ],
        "sourceText": "acebo in diabetes studies show some improvement in glycemic control, likely due to their increased compliance to dietary and exercise counseling while they are participating in a clinical study. 2 ETH"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "dapagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg",
            "description": "low dose"
          },
          {
            "amount": 10.0,
            "unit": "mg",
            "description": "high dose"
          }
        ],
        "durationDescription": "24-week double-blind short-term treatment period and 28-week long-term treatment period",
        "doseModifications": [
          "Study medication should be interrupted during sick days if necessary",
          "Reductions in insulin doses of more than 20% are not recommended regardless of glucose values"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "24-week double-blind short-term treatment period and 28-week long-term treatment period"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Insulin",
        "frequency": "PRN",
        "route": "SC",
        "startDay": 1,
        "durationDescription": "Throughout study",
        "titrationSchedule": "Adjustments of insulin dose can be made as deemed appropriate to be consistent with good medical practice; attempts must be made to titrate insulin back to baseline total daily insulin dose if reduced upon initiation.",
        "doseModifications": [
          "Reductions in insulin doses of more than 20% are not recommended regardless of glucose values",
          "Advise subjects to take extra insulin if elevated ketones are registered"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_llm_2",
        "visitName": "Week -4",
        "targetDay": -28,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 2,
        "targetWeek": -4,
        "epoch": "Screening/Lead-in"
      },
      {
        "id": "visit_6",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 5,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Screening/Lead-in",
        "sourceText": "fail any of the screening or lead-in criteria and were not subsequently randomized within the applicable study visit windows (e.g. due to a planned medical procedure, vacation plans, or employment"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Week -1",
        "targetDay": -7,
        "windowBefore": 0,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": -1,
        "epoch": "Screening/Lead-in"
      },
      {
        "id": "visit_2",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "insulin versus placebo plus adjustable insulin from baseline to Week 24 visit. "
      },
      {
        "id": "visit_3",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "cannot be avoided the daily dietary carbohydrate intake should be increased, as well as during and/or after elevated physical activity."
      },
      {
        "id": "visit_8",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "enrollment and randomization criteria will be randomized into one of the 3 blinded treatment arms (dapagliflozin 5 mg QD, dapagliflozin 10 mg QD, or placebo QD) in a 1:1:1 ratio. Randomization will be"
      },
      {
        "id": "visit_15",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "for a total of 14 days and remained confined to the inpatient unit from Day -3 to Day 7, at which point they were discharged. Subjects then had outpatient visits on Day 10, Day 14, and a discharge vis"
      },
      {
        "id": "visit_1",
        "visitName": "Week 2",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 2,
        "epoch": "Short-term Treatment",
        "sourceText": "week -4, week 2 and for the Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23) during the 24 week double blinded short term treatment period."
      },
      {
        "id": "visit_16",
        "visitName": "Day 10",
        "targetDay": 10,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "point they were discharged. Subjects then had outpatient visits on Day 10, Day 14, and a discharge visit on Day 21. In this pilot study, dapagliflozin was generally well tolerated at all doses in subj"
      },
      {
        "id": "visit_17",
        "visitName": "Day 21",
        "targetDay": 21,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "discharge visit on Day 21. In this pilot study, dapagliflozin was generally well tolerated at all doses in subjects with T1DM. Hypoglycemia events were frequent in this population during study treatme"
      },
      {
        "id": "visit_12",
        "visitName": "Week 10",
        "targetDay": 64,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 10,
        "sourceText": "in Study Flow Charts. A CGM sensor will be inserted subcutaneously at the Week -2 visit, Week -1 visit, Week 10 visit and Week 22 visit to allow monitoring for 2 weeks (for example: the Week -2 visit "
      },
      {
        "id": "visit_5",
        "visitName": "Week 11",
        "targetDay": 71,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 11,
        "epoch": "Short-term Treatment",
        "sourceText": "insertion if performed at home at week 11 and week 23  Reinforcing that all results recorded in subject diary are to be"
      },
      {
        "id": "visit_14",
        "visitName": "Week 12",
        "targetDay": 78,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "targetWeek": 12,
        "sourceText": "Week 12 (Phase 2 studies) and Week 24 (Phase 3 studies) with dapagliflozin treatment. Dapagliflozin is also associated with a significant reduction of HbA1c from baseline compared to placebo (0.4-0.56"
      },
      {
        "id": "visit_13",
        "visitName": "Week 22",
        "targetDay": 148,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 22,
        "sourceText": "visit and Week 22 visit to allow monitoring for 2 weeks (for example: the Week -2 visit to the Day 1 visit [baseline]; the Week 10 office visit until the Week 12 office visit; and the Week 22 office v"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Week 22/23 (CGM)",
        "targetDay": 155,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 7,
        "targetWeek": 22,
        "epoch": "Short-term Treatment"
      },
      {
        "id": "visit_7",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 24,
        "epoch": "Short-term Treatment",
        "sourceText": "proportion of subjects achieving an HbA1c reduction from baseline to Week 24 visit 0.5% without severe hypoglycemia events Revised Protocol No.: 02"
      },
      {
        "id": "visit_9",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "targetWeek": 52,
        "epoch": "Long-term Treatment",
        "sourceText": "Subjects will receive the last dose of study medications on Week 52 visit and they will have the last follow-up visit on Week 56 visit (30 days after Week 52 visit) Study Drug: includes both Investiga"
      },
      {
        "id": "visit_10",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "Subjects will receive the last dose of study medications on Week 52 visit and they will have the last follow-up visit on Week 56 visit (30 days after Week 52 visit) Study Drug: includes both Investiga"
      },
      {
        "id": "visit_11",
        "visitName": "Week 56",
        "targetDay": 386,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 56,
        "sourceText": "visit on Week 56 visit (30 days after Week 52 visit) Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed:"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Baseline",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "(ie, one term for each combination of all stratification factors) \nand treatment-by-week interaction, as well as the continuous fixed covariates of baseline measurement and baseline \nmeasurement-by-we"
        },
        {
          "id": "strat_llm_1",
          "name": "Current use of CGM",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Method of insulin administration at baseline",
          "categories": [
            "Multiple daily injections (MDI)",
            "Continuous subcutaneous insulin infusion (CSII)"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Baseline A1C",
          "categories": [
            "≥7.5% and < 9.0%",
            "≥9.0% and ≤10.5%"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Clinical Protocol\nMB102230\nBMS-512148\ndapagliflozin\nStudy Design: This trial is a randomized, double-blinded, three-arm, parallel-group, placebo-controlled, multicenter \ntrial to evaluate the efficacy"
    }
  }
}